CEBPA and neoplasm: Drugs targeting RNA modification were proposed as a novel strategy for tumor therapy.[26] For example, the FTO inhibitor R‐2‐hydroxyglutarate exerts anti‐tumor effects by inhibiting the proliferation of tumor cells with high expression of FTO through the FTO/m6A/MYC/CEBPA signaling pathway.[27] However, there are still few targeted drugs for NAT10‐mediated ac4C modification.